Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics.

Verheijen J, Sleegers K.

Trends Genet. 2018 Jun;34(6):434-447. doi: 10.1016/j.tig.2018.02.007. Epub 2018 Mar 21. Review.

2.

Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort.

Verheijen J, van der Zee J, Gijselinck I, Van den Bossche T, Dillen L, Heeman B, Gómez-Tortosa E, Lladó A, Sanchez-Valle R, Graff C, Pastor P, Pastor MA, Benussi L, Ghidoni R, Binetti G, Clarimon J, de Mendonça A, Gelpi E, Tsolaki M, Diehl-Schmid J, Nacmias B, Almeida MR, Borroni B, Matej R, Ruiz A, Engelborghs S, Vandenberghe R, De Deyn PP, Cruts M, Van Broeckhoven C, Sleegers K; BELNEU Consortium; EU EOD Consortium.

Neurobiol Aging. 2018 Feb;62:245.e1-245.e7. doi: 10.1016/j.neurobiolaging.2017.10.012. Epub 2017 Oct 25.

3.
4.

Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease.

De Roeck A, Van den Bossche T, van der Zee J, Verheijen J, De Coster W, Van Dongen J, Dillen L, Baradaran-Heravi Y, Heeman B, Sanchez-Valle R, Lladó A, Nacmias B, Sorbi S, Gelpi E, Grau-Rivera O, Gómez-Tortosa E, Pastor P, Ortega-Cubero S, Pastor MA, Graff C, Thonberg H, Benussi L, Ghidoni R, Binetti G, de Mendonça A, Martins M, Borroni B, Padovani A, Almeida MR, Santana I, Diehl-Schmid J, Alexopoulos P, Clarimon J, Lleó A, Fortea J, Tsolaki M, Koutroumani M, Matěj R, Rohan Z, De Deyn P, Engelborghs S, Cras P, Van Broeckhoven C, Sleegers K; European Early-Onset Dementia (EU EOD) consortium.

Acta Neuropathol. 2017 Sep;134(3):475-487. doi: 10.1007/s00401-017-1714-x. Epub 2017 Apr 27.

5.

A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease.

Verheijen J, Van den Bossche T, van der Zee J, Engelborghs S, Sanchez-Valle R, Lladó A, Graff C, Thonberg H, Pastor P, Ortega-Cubero S, Pastor MA, Benussi L, Ghidoni R, Binetti G, Clarimon J, Lleó A, Fortea J, de Mendonça A, Martins M, Grau-Rivera O, Gelpi E, Bettens K, Mateiu L, Dillen L, Cras P, De Deyn PP, Van Broeckhoven C, Sleegers K.

Acta Neuropathol. 2016 Aug;132(2):213-24. doi: 10.1007/s00401-016-1566-9. Epub 2016 Mar 30.

6.

A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42.

Sleegers K, Bettens K, De Roeck A, Van Cauwenberghe C, Cuyvers E, Verheijen J, Struyfs H, Van Dongen J, Vermeulen S, Engelborghs S, Vandenbulcke M, Vandenberghe R, De Deyn PP, Van Broeckhoven C; BELNEU consortium.

Alzheimers Dement. 2015 Dec;11(12):1452-1460. doi: 10.1016/j.jalz.2015.02.013. Epub 2015 Jun 15.

7.

Keeping the family in family planning.

Trinitapoli J, Verheijen J, Watkins S, Yeatman S.

Lancet Glob Health. 2014 Jul;2(7):e383. doi: 10.1016/S2214-109X(14)70216-5. Epub 2014 Jun 25. No abstract available.

8.

Matrix metalloproteinase-9 measured in urine from bladder cancer patients is an independent prognostic marker of poor survival.

Offersen BV, Knap MM, Horsman MR, Verheijen J, Hanemaaijer R, Overgaard J.

Acta Oncol. 2010 Nov;49(8):1283-7. doi: 10.3109/0284186X.2010.509109. Epub 2010 Sep 15.

PMID:
20843171
9.

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE, Zhang WG, Mahoney R, Gaydos C, Tardio L, Kim SK, Conant R, Curran K, Kaplan J, Verheijen J, Ayral-Kaloustian S, Mansour TS, Abraham RT, Zask A, Gibbons JJ.

Cancer Res. 2010 Jan 15;70(2):621-31. doi: 10.1158/0008-5472.CAN-09-2340. Epub 2010 Jan 12.

10.

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.

Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B, Kim J, Verheijen J, Curran K, Malwitz DJ, Cole DC, Ellingboe J, Ayral-Kaloustian S, Mansour TS, Gibbons JJ, Abraham RT, Nowak P, Zask A.

Cancer Res. 2009 Aug 1;69(15):6232-40. doi: 10.1158/0008-5472.CAN-09-0299. Epub 2009 Jul 7.

11.
12.
13.

Lack of effect of doxycycline on disease activity and joint damage in patients with rheumatoid arthritis. A double blind, placebo controlled trial.

van der Laan W, Molenaar E, Ronday K, Verheijen J, Breedveld F, Greenwald R, Dijkmans B, TeKoppele J.

J Rheumatol. 2001 Sep;28(9):1967-74.

PMID:
11550961
14.

Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo.

van der Pluijm G, Sijmons B, Vloedgraven H, van der Bent C, Drijfhout JW, Verheijen J, Quax P, Karperien M, Papapoulos S, Löwik C.

Am J Pathol. 2001 Sep;159(3):971-82.

15.

A short phosphodiester window is sufficient to direct RNase H-dependent RNA cleavage by antisense peptide nucleic acid.

Malchère C, Verheijen J, van der Laan S, Bastide L, van Boom J, Lebleu B, Robbins I.

Antisense Nucleic Acid Drug Dev. 2000 Dec;10(6):463-8.

PMID:
11198930
16.

Determination of gelatinase-A (MMP-2) activity using a novel immunocapture assay.

Capper SJ, Verheijen J, Smith L, Sully M, Visser H, Hanemaaijer R.

Ann N Y Acad Sci. 1999 Jun 30;878:487-90. No abstract available.

PMID:
10415750
17.

Differential regulation of plasminogen activation in normal keratinocytes and SCC-4 cells by fibroblasts.

Boxman IL, Quax PH, Löwik CW, Papapoulos SE, Verheijen J, Ponec M.

J Invest Dermatol. 1995 Mar;104(3):374-8.

18.

Canine intervertebral disc disease: a review of etiologic and predisposing factors.

Verheijen J, Bouw J.

Vet Q. 1982;4(3):125-34. Review.

PMID:
6755879

Supplemental Content

Loading ...
Support Center